Sun Yat-Sen

Highlights • Longitudinal ctDNA atlas during sequential chemo-radiotherapy in EBV-associated NPC •

Summary Background Certain viral infections have been linked to the development of neurodegenerative diseases.

Jia-Xi Feng Fengge Zhang and Xian Gao School of Physics and Astronomy, Sun Yat-sen University, 519082, Zhuhai, China

There is limited real-world data on cyclosporin A (CsA)-induced liver injury (CILI). This study aims to investigate the incidence, clinical classification and risk factors of CILI, thereby providing evidence to inform the treatment of CILI.

Diversifying the connecting junctions will be feasible for the controllable collaboration of metal organic frameworks (MOFs) and covalent organic frameworks (COFs) to rationally design multifunction-integrated heterostructures with enhanced performance, yet it is in the nascent stage. Herein, by intelligently exploiting the polymerization of vinyl group, C-C bond is innovatively introduced to construct the core-shell MOF@COF heterostructures with adjustable shell thickness and rare interpenetrated structure. The unique structure endows prepared C-C-linked MIL-68@COF-Vs with more superior visible-light harvesting and photogenerated carrier separation capability, leading to significantly higher photocatalytic activity and faster degradation rate than pristine MIL-68-C=Cs, COF-V, and imine-linked MIL-68-NH2@COF-V. Further, the customized MIL-68@COF-V is in-situ grown as reusable films with significantly boosted performance under ambient condition, which realize the highly efficient degradation of tetracycline within 15 min (96.5%), rhodamine 6G within 25 min (97.6%), and phenol within 40 min (95.3%) by solar drive. This work exhibits the distinctive advantages of C-C junction in the MOF@COF construction, and highlights the application prospect of rational-designed heterostructure in the treatment of persistent organic pollutants.

Cong Wang Jing Dong Heng Huang Kegui Zhou Zhenguo Liu Richard Milner

As of December 31, 2022, a total of 431 clinical trials have been initiated to study ADCs used for the pharmacotherapy of cancers, and the number of the last 10 years was 5.5 times as large as the first 11 years. These clinical trials involved 47 indications, including breast cancer, lymphoma (lymphoma, non-Hodgkin's and lymphoma, Hodgkin's), unspecified solid tumor, bladder cancer and lung cancer (lung, non-small cell cancer and lung, small cell cancer). As for each of these five indications, 50 + clinical trials have been carried out, accounting for as high as 48.50% (454/936). ADCs involve 38 targets, which are relatively concentrated. Among them, ERBB2 (HER2) and TNFRSF8 (CD30) involve in 100 + registered clinical trials, and TNFRSF17 (BCMA), NECTIN4 and CD19 in 10 + trials. The clinical trials for these five targets account for 79.02% (354/448) of the total number. Up to 93.97% (405/431) of these clinical trials explored the correlation between biomarkers and efficacy. Up to 45.91% (292/636) of Lots (lines of treatment) applied in the clinical trials were the second line. Until December 31, 2022, 54.52% (235/431) of the clinical trials have been completed or terminated.

Abstract Objective Dysphagia is common in individuals who have undergone posterior fossa tumor (PFT) resection and negatively impacts

Abstract Background As multimorbidity becomes common that imposes a considerable burden to patients, but the extent to which